Built for the new global pricing reality.
Pharmaceutical pricing and forecasting, connected. Bring patient demand, international reference pricing, US MFN and revenue into one simulation. Explore your next move with AI-assisted analysis and optimisation.
SyMAP Global Pricing
Build your model.
See the connected result.
Built to answer the questions that matter in the new global pricing landscape. SyMAP brings the components you need into one unified simulation, connecting pricing, patient demand and revenue.
How can I plan my product’s global forecast, from launch to indication expansion?
The connected result
One connected view.
A clearer decision.
Connected in this example
- IRP
- MFN
- Patient Forecasting
- Revenue Forecasting
Connect patient demand, international price changes and US policy exposure to revenue by market and channel.
Built by Symaptics, bringing pharmaceutical pricing expertise and simulation together.
Explore SyMAP Global PricingInside SyMAP 2.0
From forecast
to decision.
One product dataset. A connected view of patients, prices and revenue. Explore the results, compare policy scenarios and investigate pricing and launch strategies.
See the whole product outlook.
Connect patient demand, international prices and US policy effects in one revenue forecast. This Symara demo shows how each region contributes over time.
Plan for the next policy shift.
Compare US and international price paths as policy assumptions change. The Symara demo shows an alternative scenario against the Symara Base baseline.
Understand the demand behind the forecast.
See how launch timing, uptake and persistence shape patient demand. Explore patients on therapy across six markets in the DMD demo.
See what makes a strategy work.
Explore pricing and launch alternatives, then inspect the gains and trade-offs. In this separate demo study, US revenue gains offset reductions elsewhere.
Expert-led projects, powered by SyMAP
A decision to make?
Put our expertise to work.
Work directly with the people who built SyMAP. We scope the decision, run the analysis and deliver recommendations with the scenarios behind them.
Acquisition due diligence
Before the deal.
Understand the exposure.
in this engagement
MFN exposure and European launch viability assessed to inform a pharmaceutical company’s acquisition decision.
Global launch strategy
Before the launch.
Compare the routes.
a ten-year forecast
For a US biotech’s rare disease asset, the analysis informed a selective, retimed launch recommendation with reduced projected MFN impact.
No SyMAP licence required to commission a project.
The people behind the modelling
Pricing expertise.
Practical perspective.
Symaptics brings pharmaceutical pricing experience and modelling together, led by our founder and supported by experienced collaborators.
Meet the people behind SyMAP
Chris McDonald PhD
Director & Founder
Pricing simulation, IRP and MFN modelling.
Rosemarie Delaney PhD
Strategic Advisor & Collaborator
Global pricing, market access and strategy.
Policy & perspective
Put the pricing landscape in context.
SyMAP updated for the GLOBE final rule
Model potential rebates under the GLOBE final rule, compare pricing and launch plans, and test a hypothetical extension.
Watch the GLOBE walkthrough Read the policy analysisExplore our thinking
Follow the MFN Hub for current policy developments, or explore our perspectives on pharmaceutical pricing, international strategy and SyMAP.
Browse news & insightsSee SyMAP 2.0 in action
Your markets. Your questions.
Your next move, in SyMAP.
Explore the platform in a walkthrough tailored to your pricing challenges.